- About Us
- Nano-Social Network
- Nano Consulting
- My Account
The Board of Alltracel Pharmaceuticals Plc., ("Alltracel", or "the Company"), (AIM:AP.L), the Healthcare Innovation Group focused on the Wound Care, Oral Care and Cardiovascular Health markets, are pleased to announce today the appointment of Mr. Nick Hart as CFO and executive director to the Board. His role will focus primarily on corporate activities including mergers and acquisitions. Nick will be based at the Company's London offices.
Nick has worked in the Life Sciences sector for over twenty years and has extensive experience in completing corporate transactions, including licensing, business development and M&A.
Before joining Alltracel, Nick worked as CFO of Smart Holograms Ltd, a company developing devices for disease diagnosis and management, and for Bioscience Managers Ltd, an international Life Sciences corporate finance and advisory practice, advising companies on M&A, strategy, and licensing transactions. Prior to this he was CFO, COO and then acting CEO of Cantab Pharmaceuticals plc, where he led the merger with Xenova Group plc, both UK biotechnology companies. He has also worked for BOC Healthcare and Servier, a French pharmaceutical company.
We also announce today the resignation of Mr. Irial Finan from the Board. Irial served as a non-executive director since January 2004 and contributed invaluable advice and experience over the past few years during Alltracel's international expansion. He has decided to step down from the Board due to the increased demands of his executive commitments within the Coca Cola Group.
Further changes include the current Group Financial Controller Stuart Sands assuming Company Secretarial duties following the departure of John Fitzpatrick as Finance Director and Secretary. We would like to thank John for his contribution to the Company over the last 19 months and wish him well in his return to practice.
Commenting on these developments, Padraic O'Connor, Chairman of Alltracel said:
"On behalf of the Board and the Company, I would like to extend a warm welcome to Nick Hart whose Life Sciences background and deal experience will assist in our strategy to grow the Alltracel Group in its core markets and to explore new markets. I would also like to express our appreciation to Irial for his contribution to the Company's growth and success over the past number of years."
Nick (52) is a director of ProSpect Pharma Inc and was a director of Smart Holograms Ltd and Bioscience Managers Ltd. There are no further disclosures to be made in respect of Nick Hart under paragraph g of Schedule 2 of the AIM Rules for Companies.
About Alltracel Pharmaceuticals Plc.
Alltracel, (AIM: AP.L) ( http://www.alltracel.com ) the Healthcare Innovation Group is focused on taking proprietary technology from research right through to commercialisation in the global healthcare market.
Alltracel Pharmaceuticals Plc., ("Alltracel") was founded in 1996 and is a public company which listed on London's Alternative Investment Market in July 2001.
With corporate headquarters in Dublin, Ireland; Alltracel has a commercial office in London, England; R&D subsidiary in the Czech Republic and manufacturing facilities in Shenzhen, China. Alltracel also has a wide network of research, development and manufacturing partners in Europe, Asia and North America.
Alltracel operates via two main divisions Alltracel Healthcare Group and Alltracel Healthcare Technologies:
Alltracel Healthcare Group is focused on the commercialisation effort behind proven innovation technologies and services for the global healthcare market. Alltracel Healthcare Group has a range of stake holdings, joint ventures and wholly owned business units operating in a variety of healthcare categories including Wound Care, Oral Care, and Cardiovascular Health.
- Alltracel's specialist Oral Care subsidiary Westone (www.westoneproducts.com) is headquartered in London, England and is the leading contract supply and manufacturing partner for the European private label inter-dental market. Westone also partners with a number of leading oral care brands internationally.
- Alltracel's specialist Nanotechnology subsidiary Nanopeutics s.r.o. (www.nanopeutics.net) is headquartered in Liberec in the Czech Republic and is dedicated to the commercialisation of NanospiderTM technology for the global healthcare market.
Alltracel Healthcare Technologies specialises in innovation, research, development and the deployment of proprietary technology in the global healthcare market. Alltracel Healthcare Technologies has established a substantial intellectual property portfolio with patents in a number of healthcare applications areas.
m docTM is a trademark of Alltracel Pharmaceuticals plc.
NanospiderTM and NanopeuticsTM are trademarks controlled by Nanopeutics s.r.o.
For more information, please click here
Dublin: Denise Cronin Alltracel: +353 1 235 2162
London: Deborah Scott
Financial Dynamics: +44 207 831 3113
New York: Sean Leous
Financial Dynamics: +1 212 850 5626
Copyright © Market WireIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
Particles from outer space are wreaking low-grade havoc on personal electronics February 19th, 2017
Engineers shrink microscope to dime-sized device February 17th, 2017